SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-284841
Filing Date
2019-11-05
Accepted
2019-11-05 17:15:38
Documents
5
Period of Report
2019-10-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d823789d8k.htm 8-K 25230
2 EX-3.1 d823789dex31.htm EX-3.1 24636
3 EX-3.2 d823789dex32.htm EX-3.2 158780
4 EX-99.1 d823789dex991.htm EX-99.1 6095
5 EX-99.2 d823789dex992.htm EX-99.2 5693
  Complete submission text file 0001193125-19-284841.txt   221830
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 191194281
SIC: 2836 Biological Products, (No Diagnostic Substances)